Candel Therapeutics to Unveil Extended Phase 3 Data for Prostate Cancer Treatment at ASTRO 2026
Event summary
- Candel Therapeutics will present extended Phase 3 data for Aglatimagene besadenovec at ASTRO 2026 on September 29, 2026.
- The poster presentation focuses on immune activation in localized prostate cancer using quantitative digital pathology.
- Aglatimagene besadenovec has received Fast Track and RMAT designations from the FDA for localized prostate cancer.
The big picture
Candel Therapeutics' presentation at ASTRO 2026 comes as the company seeks to solidify its position in the competitive oncology space. The extended Phase 3 data for Aglatimagene besadenovec could influence regulatory decisions and investor confidence, particularly given the FDA's prior designations. This follows a trend of biopharmaceutical companies leveraging digital pathology to enhance clinical trial outcomes.
What we're watching
- Regulatory Pathway
- Whether the extended Phase 3 data will strengthen Aglatimagene besadenovec's regulatory approval prospects.
- Clinical Efficacy
- How the quantitative digital pathology findings will impact the perceived efficacy of the treatment.
- Market Positioning
- The pace at which Candel Therapeutics can leverage this data to differentiate itself in the prostate cancer treatment landscape.
Related topics